Market Research Life Sciences Market Research Pharmaceuticals Market Research Drug Discovery Market Research

North America Alzheimer’s Disease Therapeutics And Diagnostics Market 2022-2028

Best Price Guarantee Length Publisher Published Date SKU
from $1,500 110 Pages Triton Market Research August, 2022 TRTN17344030
Best Price Guarantee
Price from $1,500
Length 110 Pages
Publisher Triton Market Research
Published Date August, 2022
SKU TRTN17344030

North America Alzheimer’s Disease Therapeutics And Diagnostics Market 2022-2028

MARKET OUTLOOK

According to Triton Market Research, the Alzheimer’s disease therapeutics and diagnostics market in North America is estimated to grow with a CAGR of 6.82% over the forecast period from 2022 to 2028. The United States and Canada are evaluated in the market in this region.

The United States accounts for the leading share in the AD therapeutics and diagnostics market. Data from the National Institutes of Health (NIH) suggests that, nearly 5.8 million Americans were affected by Alzheimer’s disease as of 2020. Of these, approximately 5.6 million people were in the age group of 65 years or more.

Also, according to data from the US Census Bureau, the population of Americans aged 65 or older is likely to reach 88 million individuals by 2050. As the number of elderly people in the country continues to increase, the cases of Alzheimer’s will also spiral. This will enhance the demand for therapeutics and diagnostics for AD, and thus contribute to the growth of the US market.

The United States’ Food and Drug Administration has approved 4 molecules, namely, galantamine, memantine, rivastigmine, and donepezil, for Alzheimer’s disease treatment. Further, as per the National Clinical Trials Registry (NCT), there are 144 Alzheimer’s disease-associated clinical trials in the country currently ongoing across different phases. Such active efforts by authorities are expected to steer the market’s growth.

COMPETITIVE OUTLOOK

The acclaimed players in the Alzheimer’s disease therapeutics and diagnostics market are Zydus Cadila, Baxter International Inc, Merck and Co, Eisai Co Ltd, Amarantus Bioscience Holdings Inc, Allergan Plc (acquired by Abbvie), Cognoptix Inc, GE Healthcare, and Sun Pharmaceuticals Industries Ltd.


1. North America Alzheimer’s Disease Therapeutics And Diagnostics Market – Summary
2. Industry Outlook
2.1. Timeline Of Alzheimer’s Disease Therapeutics And Diagnostics Market
2.2. Phases And Sternness Of Alzheimer’s Disease
2.3. Key Insights
2.3.1. Usage Of Computed Tomography For The Diagnosis Of Alzheimer’s Disease
2.3.2. R&D Investments In Biomarkers For Early Detection Of Dementia
2.3.3. Demand For Personalized Medicines
2.4. Impact Of Covid-19 On The Alzheimer’s Disease Therapeutics And Diagnostics Market
2.5. Porter’s Five Forces Analysis
2.6. Market Attractiveness Matrix
2.7. Vendor Scorecard
2.8. Industry Components
2.8.1. Research & Development (R & D)
2.8.2. Raw Materials
2.8.3. Manufacturing
2.8.4. Distributors/Wholesalers/Retailers
2.8.5. End-user
2.9. Key Impact Analysis
2.9.1. Effectiveness
2.9.2. Price
2.9.3. Safety
2.10. Key Market Strategies
2.10.1. Acquisitions
2.10.2. Product Launches
2.10.3. Contracts & Agreements
2.10.4. Investments & Expansions
2.11. Market Drivers
2.11.1. Prevalence Of Alzheimer’s Disease
2.11.2. Rise In The Elderly Population
2.12. Market Challenges
2.12.1. Failure Of Late-stage Drugs
2.12.2. Stringent Government Regulations
2.13. Market Opportunities
2.13.1. Emergence Of New Diagnostic Technologies
2.13.2. Growing Number Of Pipeline Drugs
3. North America Alzheimer’s Disease Therapeutics And Diagnostics Market – By Therapeutics
3.1. By Drug Type
3.1.1. Marketed Drugs
3.1.2. Pipeline Drugs
3.2. By Disease Stage
3.2.1. Late Stage: Severe Ad
3.2.2. Early/Middle Stage: Mild To Moderate Ad
3.2.3. Prodromal Stage
3.3. By Generic & Branded
3.3.1. Branded
3.3.2. Generic
4. North America Alzheimer’s Disease Therapeutics And Diagnostics Market – By Diagnostics
4.1. Lumbar Puncture Test
4.2. Positron Emission Tomography
4.3. Electroencephalography
4.4. Magnetic Resonance Imaging
4.5. Computed Tomography
4.6. Blood Test
4.7. Other Diagnostics
5. North America Alzheimer’s Disease Therapeutics And Diagnostics Market – Country Outlook
5.1. United States
5.2. Canada
6. Competitive Landscape
6.1. Baxter International Inc
6.2. F. Hoffmann-la Roche Ag
6.3. Allergan Plc (Acquired By Abbvie)
6.4. Novartis Ag
6.5. Pfizer Inc
6.6. Siemens Healthineers Ag
6.7. Amarantus Bioscience Holdings Inc
6.8. Eisai Co Ltd
6.9. Eli Lilly & Company
6.10. Lupin Limited
6.11. Merck And Co
6.12. Biogen Inc
6.13. Cognoptix Inc
6.14. Ge Healthcare
6.15. Johnson And Johnson
6.16. Sun Pharmaceuticals Industries Ltd
6.17. Teva Pharmaceutical Industries Ltd
6.18. Zydus Cadila
7. Methodology & Scope
7.1. Research Scope
7.2. Sources Of Data
7.3. Research Methodology
Table List
Table 1: North America Alzheimer’s Disease Therapeutics And Diagnostics Market, Country Outlook, 2022-2028 (In $ Million)
Table 2: Market Attractiveness Matrix
Table 3: Vendor Scorecard
Table 4: Key Strategic Developments
Table 5: North America Alzheimer’s Disease Therapeutics And Diagnostics Market, By Therapeutics, 2022-2028 (In $ Million)
Table 6: North America Alzheimer’s Disease Therapeutics Market, By Drug Type, 2022-2028 (In $ Million)
Table 7: North America Alzheimer’s Disease Therapeutics Market, By Disease Stage, 2022-2028 (In $ Million)
Table 8: North America Alzheimer’s Disease Therapeutics Market, By Generic & Branded, 2022-2028 (In $ Million)
Table 9: North America Alzheimer’s Disease Therapeutics And Diagnostics Market, By Diagnostics, 2022-2028 (In $ Million)
Table 10: North America Alzheimer’s Disease Therapeutics And Diagnostics Market, Country Outlook, 2022-2028 (In $ Million)
Figure List
Figure 1: Porter’s Five Forces Analysis
Figure 2: Key Impact Analysis
Figure 3: Timeline Of Alzheimer’s Disease Therapeutics And Diagnostics
Figure 4: Industry Components
Figure 5: North America Alzheimer’s Disease Therapeutics And Diagnostics Market, By Therapeutics, 2021 & 2028 (In %)
Figure 6: North America Alzheimer’s Disease Therapeutics Market, By Drug Type, 2021 & 2028 (In %)
Figure 7: North America Alzheimer’s Disease Therapeutics Market, By Marketed Drugs, 2022-2028 (In $ Million)
Figure 8: North America Alzheimer’s Disease Therapeutics Market, By Pipeline Drugs, 2022-2028 (In $ Million)
Figure 9: North America Alzheimer’s Disease Therapeutics Market, By Disease Stage, 2021 & 2028 (In %)
Figure 10: North America Alzheimer’s Disease Therapeutics Market, By Late Stage: Severe Ad, 2022-2028 (In $ Million)
Figure 11: North America Alzheimer’s Disease Therapeutics Market, By Early/Middle Stage: Mild To Moderate Ad, 2022-2028 (In $ Million)
Figure 12: North America Alzheimer’s Disease Therapeutics Market, By Prodromal Stage, 2022-2028 (In $ Million)
Figure 13: North America Alzheimer’s Disease Therapeutics Market, By Generic & Branded, 2021 & 2028 (In %)
Figure 14: North America Alzheimer’s Disease Therapeutics Market, By Branded, 2022-2028 (In $ Million)
Figure 15: North America Alzheimer’s Disease Therapeutics Market, By Generic, 2022-2028 (In $ Million)
Figure 16: North America Alzheimer’s Disease Therapeutics And Diagnostics Market, By Diagnostics, 2021 & 2028 (In %)
Figure 17: North America Alzheimer’s Disease Diagnostics Market, By Lumbar Puncture Test, 2022-2028 (In $ Million)
Figure 18: North America Alzheimer’s Disease Diagnostics Market, By Positron Emission Tomography, 2022-2028 (In $ Million)
Figure 19: North America Alzheimer’s Disease Diagnostics Market, By Electroencephalography, 2022-2028 (In $ Million)
Figure 20: North America Alzheimer’s Disease Diagnostics Market, By Magnetic Resonance Imaging, 2022-2028 (In $ Million)
Figure 21: North America Alzheimer’s Disease Diagnostics Market, By Computed Tomography, 2022-2028 (In $ Million)
Figure 22: North America Alzheimer’s Disease Diagnostics Market, By Blood Test, 2022-2028 (In $ Million)
Figure 23: North America Alzheimer’s Disease Diagnostics Market, By Other Diagnostics, 2022-2028 (In $ Million)
Figure 24: North America Alzheimer’s Disease Therapeutics And Diagnostics Market, Country Outlook, 2021 & 2028 (In %)
Figure 25: United States Alzheimer’s Disease Therapeutics And Diagnostics Market 2022-2028 (In $ Million)
Figure 26: Canada Alzheimer’s Disease Therapeutics And Diagnostics Market 2022-2028 (In $ Million)

$1,500
$2,200

Research Assistance

US: 800.298.5699
Int'l: +1.240.747.3093
Live help
Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Other tasks

Cookie Settings